Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00761696 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
A Phase 1 study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
NCT00761696: Completed Phase 1 study, sponsored by Infinity Pharmaceuticals.
NCT00761696 is a Phase 1 study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 94 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00761696, a Phase 1 study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
Study Summary
The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies
Interventions
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT00761696 record still lists
NCT00761696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% higher).
The record links to 0 conditions, and to 1 intervention - of which IPI-926 is the first listed.
NCT00761696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00761696 about?
NCT00761696 is a clinical study titled "A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies". The primary objectives of the study are: * To determine the safety and the maximum tolerated dose (MTD) of IPI-926 * To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s) * To recommend a dose and schedule of IPI-926 for subsequent studies
What is the current status of trial NCT00761696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2008-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00761696?
The interventions under investigation include: IPI-926 (DRUG).
Who is sponsoring clinical trial NCT00761696?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00761696's enrollment target sits among peer trials
94 615th of 2000 higher than 1,377 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia